WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of CELGENE CP (CELG)

Name CELGENE CP
Year low 51.70
Year High 80.42
Symbol CELG
Last trade 69.65
Percentage change 0.00
Volume 0
Media Volume (3m) 2,975,630
PE Ratio 21.68
EPS 3.212
Market Cap 30681
Media fatt 5075
Trend fatt trend fatt graph for CELGENE CP
Media net income 1579
Trend net income trend net income for CELGENE CP
P / E P / E graph for CELGENE CP - 11 points 11
EPS EPS graph for CELGENE CP - 15 points 15
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for CELGENE CP - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for CELGENE CP - 5 points 5
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for CELGENE CP - 7 points 7
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for CELGENE CP - 12 points 12
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for CELGENE CP - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for CELGENE CP - 4 points 4
NET INC1/NET INC3 net inc1/net inc3 graph for CELGENE CP - 7 points 7
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for CELGENE CP - 3 points 3
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for CELGENE CP - 6 points 6
. . graph for CELGENE CP - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for CELGENE CP - 1 points 1
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for CELGENE CP - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for CELGENE CP - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for CELGENE CP - 1 points 1
. . graph for CELGENE CP - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for CELGENE CP - 0 points 0
SINTESE 75

GRAPHS

max price logarithm graph for CELGENE CP based on no conditions max volume linear graph for CELGENE CP based on no conditions

News

Celgene Corporation to Present at Sanford C. Bernstein`s 28th Annual Strategic Decisions Conference (May 23 - reuters) 3 Of Cramer's Top Growth Stock Picks To Buy On This Dip (May 21 - reuters) 4 High-Growth Biotech Stocks With Negative Receivable Trends (May 18 - reuters) Smart Biotech Management For Clinical Trial Paths (May 17 - reuters) 2 Healthcare Companies To Buy, 2 To Hold (May 15 - reuters) Hedging Biotechs As R&D Investment Declines (May 10 - reuters) New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma (May 10 - reuters) Celgene Sets The Stage For Patient Investors (May 09 - reuters) Top March 2012 Quarter Picks From $1 Billion Pure-Play Biotech Swiss Hedge Fund BB Biotech (May 08 - reuters) Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel (May 07 - reuters) Celgene Corporation to Present at Two Upcoming Investor Conferences (May 04 - reuters) Celgene Reports Q1 Results: Seeing Further Upside (Apr 29 - reuters) Disappointed By Celgene's Q1? Take The Long View (Apr 28 - reuters) Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and Sotheby's Released By InvestorsObserver (Apr 27 - reuters) Celgene's CEO Discusses Q1 2012 Results - Earnings Call Transcript (Apr 27 - reuters) Celgene Reports First Quarter 2012 Operating and Financial Results (Apr 26 - reuters) Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers (Apr 26 - reuters) Amgen Goes to Turkey, Loses Biotech Cred (Apr 25 - reuters) Earnings Preview: Celgene (Apr 25 - reuters) Celgene: Earnings Preview (Apr 25 - reuters) Biotechnology And Drugs Stocks To Watch Ahead Of Earnings (Apr 18 - reuters) Celgene Corporation to Announce First Quarter 2012 Results on April 26, 2012 (Apr 17 - reuters) Does Amgen Pass Buffett's Test? (Apr 15 - reuters) Analysts Actions: DOV, CELG, JCI (Apr 13 - reuters) Investors Already Expect A Lot From Ariad Pharmaceuticals (Apr 09 - reuters) Celgene's Compelling Growth Story (Apr 03 - reuters) This Cancer Drug Works, but Indication Drama Remains (Mar 30 - reuters) Critical Alerts For MasterCard, Celgene, Fossil, Safeway, and HMS Holdings By Seven Summits Research (Mar 27 - reuters) Curis: Potential Blockbuster Application In Pancreatic Cancer (Mar 20 - reuters) 10 Stocks Boosting Little Funds to Big Returns (Update2) (Mar 16 - reuters) Celgene: Healthy Growth Rate And Valuation Offers A Profitable Prescription For Above-Average Future Returns (Mar 15 - reuters) Challenging Targets Could Pay Off For Ziopharm Oncology (Mar 15 - reuters) Has Spectrum Pharmaceuticals Become the Perfect Stock? (Mar 09 - reuters) Celgene Completes Acquisition of Avila Therapeutics (Mar 08 - reuters) This Drugmaker Is Covering All Its Bills (Mar 02 - reuters) Clovis Oncology: Like the Story, Not the Stock (Feb 27 - reuters) Celgene Corporation to Present at Two Upcoming Investor Conferences (Feb 27 - reuters) 16 Rallying Healthcare Stocks Being Sold By Hedge Funds (Feb 22 - reuters) A Roadmap For Immunotherapy Success In Oncology (Feb 21 - reuters) Celgene Corporation to Present at the Citi 2012 Global Health Care Conference (Feb 21 - reuters) After Gilead's Drop: Hedging 5 Biotechnology Stocks (Feb 20 - reuters) Immunocellular Again Pushing To $2 (Feb 15 - reuters) Gilead: A Solid Investment (Feb 13 - reuters) Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation (Feb 09 - reuters) Investor Uprising IU25 Index Hits New High: Up 12% in 2012 (Feb 08 - reuters) Why Now Is The Time To Buy Healthcare Stocks (Feb 02 - reuters) Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach (Jan 30 - reuters) Celgene Meets on the Top Line, Misses Where It Counts (Jan 29 - reuters) 2 Biotech Acquisitions in 1 Day! Let's Throw a Party (Jan 28 - reuters) Analysts' Actions: CELG, HIG, JCP, JNPR (Jan 27 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY